nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—FPR1—renal system—urinary bladder cancer	0.0354	0.111	CbGeAlD
Nedocromil—PTGDR—urethra—urinary bladder cancer	0.0328	0.103	CbGeAlD
Nedocromil—CYSLTR2—female reproductive system—urinary bladder cancer	0.0315	0.0986	CbGeAlD
Nedocromil—PTGDR—vagina—urinary bladder cancer	0.0242	0.0759	CbGeAlD
Nedocromil—CYSLTR1—prostate gland—urinary bladder cancer	0.0217	0.068	CbGeAlD
Nedocromil—HSP90AA1—prostate gland—urinary bladder cancer	0.0188	0.059	CbGeAlD
Nedocromil—HSP90AA1—seminal vesicle—urinary bladder cancer	0.0159	0.0499	CbGeAlD
Nedocromil—PTGDR—lymph node—urinary bladder cancer	0.0156	0.0491	CbGeAlD
Nedocromil—CYSLTR1—smooth muscle tissue—urinary bladder cancer	0.0154	0.0482	CbGeAlD
Nedocromil—HSP90AA1—epithelium—urinary bladder cancer	0.0138	0.0434	CbGeAlD
Nedocromil—HSP90AA1—smooth muscle tissue—urinary bladder cancer	0.0133	0.0418	CbGeAlD
Nedocromil—HSP90AA1—renal system—urinary bladder cancer	0.0128	0.0402	CbGeAlD
Nedocromil—HSP90AA1—urethra—urinary bladder cancer	0.0126	0.0395	CbGeAlD
Nedocromil—CYSLTR1—female reproductive system—urinary bladder cancer	0.0118	0.0371	CbGeAlD
Nedocromil—CYSLTR1—vagina—urinary bladder cancer	0.0107	0.0336	CbGeAlD
Nedocromil—HSP90AA1—female reproductive system—urinary bladder cancer	0.0103	0.0322	CbGeAlD
Nedocromil—HSP90AA1—vagina—urinary bladder cancer	0.00929	0.0291	CbGeAlD
Nedocromil—CYSLTR1—lymph node—urinary bladder cancer	0.00693	0.0217	CbGeAlD
Nedocromil—HSP90AA1—lymph node—urinary bladder cancer	0.00601	0.0188	CbGeAlD
Nedocromil—Pneumonia—Valrubicin—urinary bladder cancer	0.006	0.0216	CcSEcCtD
Nedocromil—Chest pain—Valrubicin—urinary bladder cancer	0.00397	0.0143	CcSEcCtD
Nedocromil—Stinging—Fluorouracil—urinary bladder cancer	0.00377	0.0136	CcSEcCtD
Nedocromil—Photophobia—Thiotepa—urinary bladder cancer	0.00347	0.0125	CcSEcCtD
Nedocromil—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.00311	0.0112	CcSEcCtD
Nedocromil—Pain—Carboplatin—urinary bladder cancer	0.00301	0.0109	CcSEcCtD
Nedocromil—Abdominal pain—Valrubicin—urinary bladder cancer	0.00301	0.0108	CcSEcCtD
Nedocromil—Body temperature increased—Valrubicin—urinary bladder cancer	0.00301	0.0108	CcSEcCtD
Nedocromil—Leukopenia—Mitomycin—urinary bladder cancer	0.00288	0.0104	CcSEcCtD
Nedocromil—Photophobia—Fluorouracil—urinary bladder cancer	0.00287	0.0103	CcSEcCtD
Nedocromil—Cough—Mitomycin—urinary bladder cancer	0.0028	0.0101	CcSEcCtD
Nedocromil—Body temperature increased—Carboplatin—urinary bladder cancer	0.00279	0.01	CcSEcCtD
Nedocromil—Asthenia—Valrubicin—urinary bladder cancer	0.00273	0.00984	CcSEcCtD
Nedocromil—Diarrhoea—Valrubicin—urinary bladder cancer	0.0026	0.00939	CcSEcCtD
Nedocromil—Dizziness—Valrubicin—urinary bladder cancer	0.00252	0.00907	CcSEcCtD
Nedocromil—Vomiting—Valrubicin—urinary bladder cancer	0.00242	0.00872	CcSEcCtD
Nedocromil—Rash—Valrubicin—urinary bladder cancer	0.0024	0.00865	CcSEcCtD
Nedocromil—Dermatitis—Valrubicin—urinary bladder cancer	0.0024	0.00864	CcSEcCtD
Nedocromil—Headache—Valrubicin—urinary bladder cancer	0.00238	0.00859	CcSEcCtD
Nedocromil—Dyspnoea—Mitomycin—urinary bladder cancer	0.00234	0.00843	CcSEcCtD
Nedocromil—Nasal congestion—Cisplatin—urinary bladder cancer	0.00231	0.00832	CcSEcCtD
Nedocromil—Nausea—Valrubicin—urinary bladder cancer	0.00226	0.00815	CcSEcCtD
Nedocromil—Fatigue—Mitomycin—urinary bladder cancer	0.00226	0.00815	CcSEcCtD
Nedocromil—Pain—Mitomycin—urinary bladder cancer	0.00224	0.00808	CcSEcCtD
Nedocromil—Pneumonia—Thiotepa—urinary bladder cancer	0.00208	0.00749	CcSEcCtD
Nedocromil—Body temperature increased—Mitomycin—urinary bladder cancer	0.00207	0.00747	CcSEcCtD
Nedocromil—Conjunctivitis—Thiotepa—urinary bladder cancer	0.00201	0.00724	CcSEcCtD
Nedocromil—Influenza—Gemcitabine—urinary bladder cancer	0.00195	0.00703	CcSEcCtD
Nedocromil—Rash erythematous—Epirubicin—urinary bladder cancer	0.00194	0.007	CcSEcCtD
Nedocromil—Otitis media—Epirubicin—urinary bladder cancer	0.00191	0.00689	CcSEcCtD
Nedocromil—Eosinophilia—Fluorouracil—urinary bladder cancer	0.0019	0.00684	CcSEcCtD
Nedocromil—Feeling hot—Epirubicin—urinary bladder cancer	0.0019	0.00683	CcSEcCtD
Nedocromil—Asthenia—Mitomycin—urinary bladder cancer	0.00188	0.00678	CcSEcCtD
Nedocromil—Stinging—Epirubicin—urinary bladder cancer	0.00184	0.00662	CcSEcCtD
Nedocromil—Dysphonia—Epirubicin—urinary bladder cancer	0.00181	0.00652	CcSEcCtD
Nedocromil—Rash erythematous—Doxorubicin—urinary bladder cancer	0.0018	0.00648	CcSEcCtD
Nedocromil—Diarrhoea—Mitomycin—urinary bladder cancer	0.00179	0.00647	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.00178	0.00642	CcSEcCtD
Nedocromil—Otitis media—Doxorubicin—urinary bladder cancer	0.00177	0.00637	CcSEcCtD
Nedocromil—Feeling hot—Doxorubicin—urinary bladder cancer	0.00175	0.00632	CcSEcCtD
Nedocromil—Pneumonia—Gemcitabine—urinary bladder cancer	0.00175	0.0063	CcSEcCtD
Nedocromil—Dizziness—Mitomycin—urinary bladder cancer	0.00173	0.00625	CcSEcCtD
Nedocromil—Pneumonia—Fluorouracil—urinary bladder cancer	0.00172	0.0062	CcSEcCtD
Nedocromil—Stinging—Doxorubicin—urinary bladder cancer	0.0017	0.00613	CcSEcCtD
Nedocromil—Dysphonia—Doxorubicin—urinary bladder cancer	0.00167	0.00603	CcSEcCtD
Nedocromil—Vomiting—Mitomycin—urinary bladder cancer	0.00167	0.00601	CcSEcCtD
Nedocromil—Conjunctivitis—Fluorouracil—urinary bladder cancer	0.00166	0.00599	CcSEcCtD
Nedocromil—Rash—Mitomycin—urinary bladder cancer	0.00165	0.00596	CcSEcCtD
Nedocromil—Dermatitis—Mitomycin—urinary bladder cancer	0.00165	0.00595	CcSEcCtD
Nedocromil—Viral infection—Epirubicin—urinary bladder cancer	0.00165	0.00594	CcSEcCtD
Nedocromil—Headache—Mitomycin—urinary bladder cancer	0.00164	0.00592	CcSEcCtD
Nedocromil—Cough increased—Epirubicin—urinary bladder cancer	0.00163	0.00586	CcSEcCtD
Nedocromil—Sinusitis—Fluorouracil—urinary bladder cancer	0.0016	0.00578	CcSEcCtD
Nedocromil—Conjunctivitis—Cisplatin—urinary bladder cancer	0.00158	0.00568	CcSEcCtD
Nedocromil—Rhinitis—Gemcitabine—urinary bladder cancer	0.00157	0.00564	CcSEcCtD
Nedocromil—Nausea—Mitomycin—urinary bladder cancer	0.00156	0.00561	CcSEcCtD
Nedocromil—Pharyngitis—Gemcitabine—urinary bladder cancer	0.00155	0.00558	CcSEcCtD
Nedocromil—Rhinitis—Fluorouracil—urinary bladder cancer	0.00154	0.00555	CcSEcCtD
Nedocromil—Viral infection—Doxorubicin—urinary bladder cancer	0.00152	0.00549	CcSEcCtD
Nedocromil—Pharyngitis—Fluorouracil—urinary bladder cancer	0.00152	0.00549	CcSEcCtD
Nedocromil—Cough increased—Doxorubicin—urinary bladder cancer	0.0015	0.00542	CcSEcCtD
Nedocromil—Pneumonia—Etoposide—urinary bladder cancer	0.00149	0.00538	CcSEcCtD
Nedocromil—Leukopenia—Thiotepa—urinary bladder cancer	0.00145	0.00521	CcSEcCtD
Nedocromil—Cough—Thiotepa—urinary bladder cancer	0.00141	0.00508	CcSEcCtD
Nedocromil—Visual impairment—Cisplatin—urinary bladder cancer	0.0014	0.00505	CcSEcCtD
Nedocromil—Leukopenia—Gemcitabine—urinary bladder cancer	0.00122	0.00438	CcSEcCtD
Nedocromil—Eczema—Epirubicin—urinary bladder cancer	0.0012	0.00433	CcSEcCtD
Nedocromil—Leukopenia—Fluorouracil—urinary bladder cancer	0.0012	0.00431	CcSEcCtD
Nedocromil—Tremor—Cisplatin—urinary bladder cancer	0.00119	0.00428	CcSEcCtD
Nedocromil—Cough—Gemcitabine—urinary bladder cancer	0.00119	0.00427	CcSEcCtD
Nedocromil—Dyspepsia—Thiotepa—urinary bladder cancer	0.00116	0.00418	CcSEcCtD
Nedocromil—Chest pain—Gemcitabine—urinary bladder cancer	0.00116	0.00417	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00114	0.0041	CcSEcCtD
Nedocromil—Chest pain—Fluorouracil—urinary bladder cancer	0.00114	0.0041	CcSEcCtD
Nedocromil—Fatigue—Thiotepa—urinary bladder cancer	0.00114	0.0041	CcSEcCtD
Nedocromil—Dysgeusia—Etoposide—urinary bladder cancer	0.00114	0.0041	CcSEcCtD
Nedocromil—Leukopenia—Cisplatin—urinary bladder cancer	0.00113	0.00409	CcSEcCtD
Nedocromil—Pain—Thiotepa—urinary bladder cancer	0.00113	0.00406	CcSEcCtD
Nedocromil—Eczema—Doxorubicin—urinary bladder cancer	0.00111	0.00401	CcSEcCtD
Nedocromil—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00111	0.004	CcSEcCtD
Nedocromil—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00109	0.00393	CcSEcCtD
Nedocromil—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00108	0.00389	CcSEcCtD
Nedocromil—Urticaria—Thiotepa—urinary bladder cancer	0.00105	0.00378	CcSEcCtD
Nedocromil—Abdominal pain—Thiotepa—urinary bladder cancer	0.00104	0.00376	CcSEcCtD
Nedocromil—Body temperature increased—Thiotepa—urinary bladder cancer	0.00104	0.00376	CcSEcCtD
Nedocromil—Leukopenia—Etoposide—urinary bladder cancer	0.00104	0.00374	CcSEcCtD
Nedocromil—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00103	0.00373	CcSEcCtD
Nedocromil—Cough—Etoposide—urinary bladder cancer	0.00101	0.00365	CcSEcCtD
Nedocromil—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000989	0.00356	CcSEcCtD
Nedocromil—Chest pain—Etoposide—urinary bladder cancer	0.000988	0.00356	CcSEcCtD
Nedocromil—Eosinophilia—Methotrexate—urinary bladder cancer	0.000988	0.00356	CcSEcCtD
Nedocromil—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000972	0.0035	CcSEcCtD
Nedocromil—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000972	0.0035	CcSEcCtD
Nedocromil—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00096	0.00346	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000958	0.00345	CcSEcCtD
Nedocromil—Fatigue—Gemcitabine—urinary bladder cancer	0.000956	0.00345	CcSEcCtD
Nedocromil—Pain—Gemcitabine—urinary bladder cancer	0.000949	0.00342	CcSEcCtD
Nedocromil—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000947	0.00341	CcSEcCtD
Nedocromil—Asthenia—Thiotepa—urinary bladder cancer	0.000946	0.00341	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000942	0.00339	CcSEcCtD
Nedocromil—Influenza—Epirubicin—urinary bladder cancer	0.000934	0.00337	CcSEcCtD
Nedocromil—Pain—Fluorouracil—urinary bladder cancer	0.000933	0.00336	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000927	0.00334	CcSEcCtD
Nedocromil—Eosinophilia—Epirubicin—urinary bladder cancer	0.000925	0.00333	CcSEcCtD
Nedocromil—Dyspnoea—Cisplatin—urinary bladder cancer	0.000922	0.00332	CcSEcCtD
Nedocromil—Diarrhoea—Thiotepa—urinary bladder cancer	0.000902	0.00325	CcSEcCtD
Nedocromil—Bronchitis—Epirubicin—urinary bladder cancer	0.000898	0.00324	CcSEcCtD
Nedocromil—Pneumonia—Methotrexate—urinary bladder cancer	0.000895	0.00322	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000893	0.00322	CcSEcCtD
Nedocromil—Pain—Cisplatin—urinary bladder cancer	0.000884	0.00319	CcSEcCtD
Nedocromil—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000877	0.00316	CcSEcCtD
Nedocromil—Dizziness—Thiotepa—urinary bladder cancer	0.000872	0.00314	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000868	0.00313	CcSEcCtD
Nedocromil—Urticaria—Fluorouracil—urinary bladder cancer	0.000867	0.00312	CcSEcCtD
Nedocromil—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000865	0.00312	CcSEcCtD
Nedocromil—Influenza—Doxorubicin—urinary bladder cancer	0.000864	0.00311	CcSEcCtD
Nedocromil—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000862	0.00311	CcSEcCtD
Nedocromil—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000855	0.00308	CcSEcCtD
Nedocromil—Dyspnoea—Etoposide—urinary bladder cancer	0.000845	0.00304	CcSEcCtD
Nedocromil—Vomiting—Thiotepa—urinary bladder cancer	0.000839	0.00302	CcSEcCtD
Nedocromil—Pneumonia—Epirubicin—urinary bladder cancer	0.000837	0.00302	CcSEcCtD
Nedocromil—Rash—Thiotepa—urinary bladder cancer	0.000832	0.003	CcSEcCtD
Nedocromil—Bronchitis—Doxorubicin—urinary bladder cancer	0.000831	0.00299	CcSEcCtD
Nedocromil—Dermatitis—Thiotepa—urinary bladder cancer	0.000831	0.00299	CcSEcCtD
Nedocromil—Headache—Thiotepa—urinary bladder cancer	0.000826	0.00298	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000818	0.00295	CcSEcCtD
Nedocromil—Body temperature increased—Cisplatin—urinary bladder cancer	0.000817	0.00295	CcSEcCtD
Nedocromil—Fatigue—Etoposide—urinary bladder cancer	0.000817	0.00294	CcSEcCtD
Nedocromil—Pain—Etoposide—urinary bladder cancer	0.00081	0.00292	CcSEcCtD
Nedocromil—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000809	0.00292	CcSEcCtD
Nedocromil—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000804	0.0029	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000803	0.00289	CcSEcCtD
Nedocromil—Asthenia—Gemcitabine—urinary bladder cancer	0.000796	0.00287	CcSEcCtD
Nedocromil—Pharyngitis—Methotrexate—urinary bladder cancer	0.000793	0.00286	CcSEcCtD
Nedocromil—Nausea—Thiotepa—urinary bladder cancer	0.000783	0.00282	CcSEcCtD
Nedocromil—Sinusitis—Epirubicin—urinary bladder cancer	0.000781	0.00281	CcSEcCtD
Nedocromil—Pneumonia—Doxorubicin—urinary bladder cancer	0.000775	0.00279	CcSEcCtD
Nedocromil—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000775	0.00279	CcSEcCtD
Nedocromil—Visual impairment—Methotrexate—urinary bladder cancer	0.00077	0.00277	CcSEcCtD
Nedocromil—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000762	0.00275	CcSEcCtD
Nedocromil—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000759	0.00274	CcSEcCtD
Nedocromil—Urticaria—Etoposide—urinary bladder cancer	0.000753	0.00271	CcSEcCtD
Nedocromil—Rhinitis—Epirubicin—urinary bladder cancer	0.000749	0.0027	CcSEcCtD
Nedocromil—Body temperature increased—Etoposide—urinary bladder cancer	0.000749	0.0027	CcSEcCtD
Nedocromil—Abdominal pain—Etoposide—urinary bladder cancer	0.000749	0.0027	CcSEcCtD
Nedocromil—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000749	0.0027	CcSEcCtD
Nedocromil—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000746	0.00269	CcSEcCtD
Nedocromil—Asthenia—Cisplatin—urinary bladder cancer	0.000742	0.00267	CcSEcCtD
Nedocromil—Pharyngitis—Epirubicin—urinary bladder cancer	0.000742	0.00267	CcSEcCtD
Nedocromil—Sinusitis—Doxorubicin—urinary bladder cancer	0.000723	0.0026	CcSEcCtD
Nedocromil—Dizziness—Fluorouracil—urinary bladder cancer	0.000721	0.0026	CcSEcCtD
Nedocromil—Visual impairment—Epirubicin—urinary bladder cancer	0.00072	0.0026	CcSEcCtD
Nedocromil—Diarrhoea—Cisplatin—urinary bladder cancer	0.000708	0.00255	CcSEcCtD
Nedocromil—Vomiting—Gemcitabine—urinary bladder cancer	0.000705	0.00254	CcSEcCtD
Nedocromil—Rash—Gemcitabine—urinary bladder cancer	0.0007	0.00252	CcSEcCtD
Nedocromil—Dermatitis—Gemcitabine—urinary bladder cancer	0.000699	0.00252	CcSEcCtD
Nedocromil—Hypersensitivity—Etoposide—urinary bladder cancer	0.000698	0.00252	CcSEcCtD
Nedocromil—Headache—Gemcitabine—urinary bladder cancer	0.000695	0.0025	CcSEcCtD
Nedocromil—Vomiting—Fluorouracil—urinary bladder cancer	0.000694	0.0025	CcSEcCtD
Nedocromil—Rhinitis—Doxorubicin—urinary bladder cancer	0.000693	0.0025	CcSEcCtD
Nedocromil—Rash—Fluorouracil—urinary bladder cancer	0.000688	0.00248	CcSEcCtD
Nedocromil—Dermatitis—Fluorouracil—urinary bladder cancer	0.000687	0.00248	CcSEcCtD
Nedocromil—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000686	0.00247	CcSEcCtD
Nedocromil—Headache—Fluorouracil—urinary bladder cancer	0.000683	0.00246	CcSEcCtD
Nedocromil—Dysgeusia—Methotrexate—urinary bladder cancer	0.000681	0.00245	CcSEcCtD
Nedocromil—Asthenia—Etoposide—urinary bladder cancer	0.00068	0.00245	CcSEcCtD
Nedocromil—Visual impairment—Doxorubicin—urinary bladder cancer	0.000666	0.0024	CcSEcCtD
Nedocromil—Nausea—Gemcitabine—urinary bladder cancer	0.000659	0.00237	CcSEcCtD
Nedocromil—Vomiting—Cisplatin—urinary bladder cancer	0.000657	0.00237	CcSEcCtD
Nedocromil—Rash—Cisplatin—urinary bladder cancer	0.000652	0.00235	CcSEcCtD
Nedocromil—Dermatitis—Cisplatin—urinary bladder cancer	0.000651	0.00235	CcSEcCtD
Nedocromil—Diarrhoea—Etoposide—urinary bladder cancer	0.000648	0.00234	CcSEcCtD
Nedocromil—Nausea—Fluorouracil—urinary bladder cancer	0.000648	0.00233	CcSEcCtD
Nedocromil—Dysgeusia—Epirubicin—urinary bladder cancer	0.000637	0.0023	CcSEcCtD
Nedocromil—Dizziness—Etoposide—urinary bladder cancer	0.000626	0.00226	CcSEcCtD
Nedocromil—Leukopenia—Methotrexate—urinary bladder cancer	0.000622	0.00224	CcSEcCtD
Nedocromil—Nausea—Cisplatin—urinary bladder cancer	0.000614	0.00221	CcSEcCtD
Nedocromil—Cough—Methotrexate—urinary bladder cancer	0.000607	0.00219	CcSEcCtD
Nedocromil—Vomiting—Etoposide—urinary bladder cancer	0.000602	0.00217	CcSEcCtD
Nedocromil—Rash—Etoposide—urinary bladder cancer	0.000597	0.00215	CcSEcCtD
Nedocromil—Dermatitis—Etoposide—urinary bladder cancer	0.000597	0.00215	CcSEcCtD
Nedocromil—Headache—Etoposide—urinary bladder cancer	0.000593	0.00214	CcSEcCtD
Nedocromil—Chest pain—Methotrexate—urinary bladder cancer	0.000592	0.00213	CcSEcCtD
Nedocromil—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00059	0.00212	CcSEcCtD
Nedocromil—Leukopenia—Epirubicin—urinary bladder cancer	0.000582	0.0021	CcSEcCtD
Nedocromil—Cough—Epirubicin—urinary bladder cancer	0.000568	0.00205	CcSEcCtD
Nedocromil—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000567	0.00204	CcSEcCtD
Nedocromil—Nausea—Etoposide—urinary bladder cancer	0.000563	0.00203	CcSEcCtD
Nedocromil—Chest pain—Epirubicin—urinary bladder cancer	0.000554	0.002	CcSEcCtD
Nedocromil—Dry mouth—Epirubicin—urinary bladder cancer	0.000542	0.00195	CcSEcCtD
Nedocromil—Leukopenia—Doxorubicin—urinary bladder cancer	0.000539	0.00194	CcSEcCtD
Nedocromil—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000531	0.00191	CcSEcCtD
Nedocromil—Cough—Doxorubicin—urinary bladder cancer	0.000525	0.00189	CcSEcCtD
Nedocromil—Chest pain—Doxorubicin—urinary bladder cancer	0.000513	0.00185	CcSEcCtD
Nedocromil—Dyspnoea—Methotrexate—urinary bladder cancer	0.000506	0.00182	CcSEcCtD
Nedocromil—Dry mouth—Doxorubicin—urinary bladder cancer	0.000501	0.00181	CcSEcCtD
Nedocromil—Dyspepsia—Methotrexate—urinary bladder cancer	0.000499	0.0018	CcSEcCtD
Nedocromil—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000491	0.00177	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00049	0.00177	CcSEcCtD
Nedocromil—Fatigue—Methotrexate—urinary bladder cancer	0.000489	0.00176	CcSEcCtD
Nedocromil—Pain—Methotrexate—urinary bladder cancer	0.000485	0.00175	CcSEcCtD
Nedocromil—Dyspnoea—Epirubicin—urinary bladder cancer	0.000473	0.00171	CcSEcCtD
Nedocromil—Dyspepsia—Epirubicin—urinary bladder cancer	0.000467	0.00168	CcSEcCtD
Nedocromil—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000464	0.00167	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000458	0.00165	CcSEcCtD
Nedocromil—Fatigue—Epirubicin—urinary bladder cancer	0.000458	0.00165	CcSEcCtD
Nedocromil—Pain—Epirubicin—urinary bladder cancer	0.000454	0.00164	CcSEcCtD
Nedocromil—Urticaria—Methotrexate—urinary bladder cancer	0.000451	0.00162	CcSEcCtD
Nedocromil—Body temperature increased—Methotrexate—urinary bladder cancer	0.000449	0.00162	CcSEcCtD
Nedocromil—Abdominal pain—Methotrexate—urinary bladder cancer	0.000449	0.00162	CcSEcCtD
Nedocromil—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000438	0.00158	CcSEcCtD
Nedocromil—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000434	0.00156	CcSEcCtD
Nedocromil—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000433	0.00156	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000424	0.00153	CcSEcCtD
Nedocromil—Fatigue—Doxorubicin—urinary bladder cancer	0.000424	0.00153	CcSEcCtD
Nedocromil—Urticaria—Epirubicin—urinary bladder cancer	0.000422	0.00152	CcSEcCtD
Nedocromil—Pain—Doxorubicin—urinary bladder cancer	0.00042	0.00151	CcSEcCtD
Nedocromil—Body temperature increased—Epirubicin—urinary bladder cancer	0.00042	0.00151	CcSEcCtD
Nedocromil—Abdominal pain—Epirubicin—urinary bladder cancer	0.00042	0.00151	CcSEcCtD
Nedocromil—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000418	0.00151	CcSEcCtD
Nedocromil—Asthenia—Methotrexate—urinary bladder cancer	0.000407	0.00147	CcSEcCtD
Nedocromil—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000402	0.00145	CcSEcCtD
Nedocromil—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000391	0.00141	CcSEcCtD
Nedocromil—Urticaria—Doxorubicin—urinary bladder cancer	0.00039	0.00141	CcSEcCtD
Nedocromil—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000388	0.0014	CcSEcCtD
Nedocromil—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000388	0.0014	CcSEcCtD
Nedocromil—Diarrhoea—Methotrexate—urinary bladder cancer	0.000388	0.0014	CcSEcCtD
Nedocromil—Asthenia—Epirubicin—urinary bladder cancer	0.000381	0.00137	CcSEcCtD
Nedocromil—PTGDR—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000377	0.000934	CbGpPWpGaD
Nedocromil—Dizziness—Methotrexate—urinary bladder cancer	0.000375	0.00135	CcSEcCtD
Nedocromil—FPR1—GPCR downstream signaling—IL2—urinary bladder cancer	0.000373	0.000924	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—NCOR1—urinary bladder cancer	0.00037	0.000916	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—KRAS—urinary bladder cancer	0.000366	0.000907	CbGpPWpGaD
Nedocromil—Diarrhoea—Epirubicin—urinary bladder cancer	0.000363	0.00131	CcSEcCtD
Nedocromil—CYSLTR1—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000363	0.000899	CbGpPWpGaD
Nedocromil—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000362	0.0013	CcSEcCtD
Nedocromil—Vomiting—Methotrexate—urinary bladder cancer	0.000361	0.0013	CcSEcCtD
Nedocromil—PTGDR—GPCR downstream signaling—IL2—urinary bladder cancer	0.00036	0.000892	CbGpPWpGaD
Nedocromil—Rash—Methotrexate—urinary bladder cancer	0.000358	0.00129	CcSEcCtD
Nedocromil—Dermatitis—Methotrexate—urinary bladder cancer	0.000357	0.00129	CcSEcCtD
Nedocromil—Headache—Methotrexate—urinary bladder cancer	0.000355	0.00128	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	0.000355	0.000878	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000354	0.000878	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TERT—urinary bladder cancer	0.000354	0.000878	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—CDKN1A—urinary bladder cancer	0.000353	0.000875	CbGpPWpGaD
Nedocromil—Asthenia—Doxorubicin—urinary bladder cancer	0.000353	0.00127	CcSEcCtD
Nedocromil—Dizziness—Epirubicin—urinary bladder cancer	0.000351	0.00127	CcSEcCtD
Nedocromil—HSP90AA1—Axon guidance—ERBB2—urinary bladder cancer	0.000351	0.000869	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—NAT2—urinary bladder cancer	0.00035	0.000866	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—RBX1—urinary bladder cancer	0.000343	0.000849	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—CDK4—urinary bladder cancer	0.000342	0.000848	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000342	0.000848	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—IL2—urinary bladder cancer	0.000339	0.000839	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by ERBB2—HRAS—urinary bladder cancer	0.000338	0.000838	CbGpPWpGaD
Nedocromil—Vomiting—Epirubicin—urinary bladder cancer	0.000338	0.00122	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—TERT—urinary bladder cancer	0.000337	0.000836	CbGpPWpGaD
Nedocromil—Nausea—Methotrexate—urinary bladder cancer	0.000337	0.00121	CcSEcCtD
Nedocromil—CYSLTR2—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000337	0.000835	CbGpPWpGaD
Nedocromil—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000336	0.00121	CcSEcCtD
Nedocromil—HSP90AA1—Cellular responses to stress—EP300—urinary bladder cancer	0.000336	0.000832	CbGpPWpGaD
Nedocromil—Rash—Epirubicin—urinary bladder cancer	0.000335	0.00121	CcSEcCtD
Nedocromil—Dermatitis—Epirubicin—urinary bladder cancer	0.000335	0.00121	CcSEcCtD
Nedocromil—HSP90AA1—Disease—ENO2—urinary bladder cancer	0.000334	0.000827	CbGpPWpGaD
Nedocromil—Headache—Epirubicin—urinary bladder cancer	0.000333	0.0012	CcSEcCtD
Nedocromil—PTGDR—Signaling by GPCR—IL2—urinary bladder cancer	0.000327	0.00081	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TERT—urinary bladder cancer	0.000326	0.000807	CbGpPWpGaD
Nedocromil—Dizziness—Doxorubicin—urinary bladder cancer	0.000325	0.00117	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—GLI1—urinary bladder cancer	0.000323	0.000801	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—S100B—urinary bladder cancer	0.000323	0.0008	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—ATM—urinary bladder cancer	0.000318	0.000789	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—CDK4—urinary bladder cancer	0.000317	0.000785	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—RBX1—urinary bladder cancer	0.000316	0.000784	CbGpPWpGaD
Nedocromil—Nausea—Epirubicin—urinary bladder cancer	0.000315	0.00114	CcSEcCtD
Nedocromil—Vomiting—Doxorubicin—urinary bladder cancer	0.000312	0.00113	CcSEcCtD
Nedocromil—HSP90AA1—Developmental Biology—PPARG—urinary bladder cancer	0.000311	0.000771	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—HRAS—urinary bladder cancer	0.000311	0.000771	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—FGFR3—urinary bladder cancer	0.00031	0.000768	CbGpPWpGaD
Nedocromil—Rash—Doxorubicin—urinary bladder cancer	0.00031	0.00112	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—FGFR3—urinary bladder cancer	0.00031	0.000767	CbGpPWpGaD
Nedocromil—Dermatitis—Doxorubicin—urinary bladder cancer	0.00031	0.00112	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—RBX1—urinary bladder cancer	0.000309	0.000765	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—RB1—urinary bladder cancer	0.000308	0.000764	CbGpPWpGaD
Nedocromil—Headache—Doxorubicin—urinary bladder cancer	0.000308	0.00111	CcSEcCtD
Nedocromil—CYSLTR2—Signaling by GPCR—RHOA—urinary bladder cancer	0.000306	0.000758	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—RRM2—urinary bladder cancer	0.000302	0.000748	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—MMP9—urinary bladder cancer	0.000301	0.000745	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—ESR1—urinary bladder cancer	0.000301	0.000745	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—FGFR3—urinary bladder cancer	0.000299	0.000741	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—CREBBP—urinary bladder cancer	0.000299	0.00074	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000296	0.000733	CbGpPWpGaD
Nedocromil—Nausea—Doxorubicin—urinary bladder cancer	0.000292	0.00105	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—ESR1—urinary bladder cancer	0.00029	0.00072	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TSC1—urinary bladder cancer	0.00029	0.000719	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NCOR1—urinary bladder cancer	0.00029	0.000719	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—JAG1—urinary bladder cancer	0.000283	0.000702	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—IL2—urinary bladder cancer	0.000283	0.0007	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—HPGDS—urinary bladder cancer	0.000279	0.000692	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ENO2—urinary bladder cancer	0.000279	0.000692	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—SRC—urinary bladder cancer	0.000277	0.000687	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—JAG1—urinary bladder cancer	0.000276	0.000684	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—RB1—urinary bladder cancer	0.000276	0.000683	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GSTT1—urinary bladder cancer	0.000271	0.000672	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	0.000271	0.000671	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—RHOA—urinary bladder cancer	0.00027	0.00067	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000269	0.000665	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—CREBBP—urinary bladder cancer	0.000264	0.000654	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CREBBP—urinary bladder cancer	0.000264	0.000653	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IFNA2—urinary bladder cancer	0.000263	0.000651	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IGF1—urinary bladder cancer	0.00026	0.000645	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—EGFR—urinary bladder cancer	0.000259	0.000642	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—IL2—urinary bladder cancer	0.000257	0.000636	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TERT—urinary bladder cancer	0.000256	0.000634	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CREBBP—urinary bladder cancer	0.000255	0.000631	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IGF1—urinary bladder cancer	0.000251	0.000623	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—ERBB2—urinary bladder cancer	0.00025	0.00062	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—EGFR—urinary bladder cancer	0.00025	0.00062	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—S100B—urinary bladder cancer	0.000248	0.000615	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—KRAS—urinary bladder cancer	0.000245	0.000606	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—EGFR—urinary bladder cancer	0.000243	0.000602	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—CDKN2A—urinary bladder cancer	0.000242	0.0006	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—TP53—urinary bladder cancer	0.00024	0.000596	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—RHOA—urinary bladder cancer	0.000238	0.000591	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—KRAS—urinary bladder cancer	0.000236	0.000586	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—FGFR3—urinary bladder cancer	0.000235	0.000581	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000234	0.000579	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—RHOA—urinary bladder cancer	0.00023	0.000571	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—KRAS—urinary bladder cancer	0.00023	0.000569	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	0.000229	0.000567	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—ESR1—urinary bladder cancer	0.000228	0.000565	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—NQO1—urinary bladder cancer	0.000225	0.000558	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—S100B—urinary bladder cancer	0.000224	0.000554	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RBX1—urinary bladder cancer	0.000222	0.000549	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	0.000221	0.000549	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—ERBB2—urinary bladder cancer	0.000221	0.000548	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—ERBB2—urinary bladder cancer	0.000221	0.000547	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—MMP9—urinary bladder cancer	0.000215	0.000532	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—ERBB2—urinary bladder cancer	0.000213	0.000528	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—RHOA—urinary bladder cancer	0.000212	0.000525	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—EP300—urinary bladder cancer	0.000211	0.000522	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CXCL8—urinary bladder cancer	0.000209	0.000519	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TSC1—urinary bladder cancer	0.000208	0.000516	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—HRAS—urinary bladder cancer	0.000208	0.000515	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NCOR1—urinary bladder cancer	0.000206	0.000511	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000205	0.000508	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—CCND1—urinary bladder cancer	0.000205	0.000507	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—EP300—urinary bladder cancer	0.000204	0.000504	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CXCL8—urinary bladder cancer	0.000202	0.000501	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NCOR1—urinary bladder cancer	0.000201	0.000498	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—HRAS—urinary bladder cancer	0.000201	0.000498	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL2—urinary bladder cancer	0.0002	0.000496	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CREBBP—urinary bladder cancer	0.0002	0.000495	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—JAG1—urinary bladder cancer	0.000198	0.000491	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—CDKN1A—urinary bladder cancer	0.000198	0.000491	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—SRC—urinary bladder cancer	0.000198	0.00049	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IGF1—urinary bladder cancer	0.000197	0.000489	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—EGFR—urinary bladder cancer	0.000196	0.000486	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—IL2—urinary bladder cancer	0.000196	0.000485	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—HRAS—urinary bladder cancer	0.000195	0.000484	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CCND1—urinary bladder cancer	0.000195	0.000483	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—ERCC2—urinary bladder cancer	0.000194	0.00048	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL2—urinary bladder cancer	0.000193	0.000479	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MMP9—urinary bladder cancer	0.000189	0.000469	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—CDKN1A—urinary bladder cancer	0.000189	0.000468	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000189	0.000467	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PTEN—urinary bladder cancer	0.000188	0.000467	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—EP300—urinary bladder cancer	0.000188	0.000467	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CCND1—urinary bladder cancer	0.000188	0.000467	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PTEN—urinary bladder cancer	0.000188	0.000466	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GSTP1—urinary bladder cancer	0.000188	0.000465	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000186	0.000461	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—KRAS—urinary bladder cancer	0.000185	0.000459	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—MYC—urinary bladder cancer	0.000184	0.000455	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MMP9—urinary bladder cancer	0.000183	0.000453	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000182	0.000451	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MTHFR—urinary bladder cancer	0.000182	0.000451	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PTEN—urinary bladder cancer	0.000182	0.00045	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TERT—urinary bladder cancer	0.000182	0.00045	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—RHOA—urinary bladder cancer	0.000181	0.000448	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—FGFR3—urinary bladder cancer	0.000181	0.000447	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—EP300—urinary bladder cancer	0.00018	0.000445	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—EP300—urinary bladder cancer	0.00018	0.000445	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL2—urinary bladder cancer	0.000178	0.000441	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TERT—urinary bladder cancer	0.000177	0.000439	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—SRC—urinary bladder cancer	0.000175	0.000433	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—TYMS—urinary bladder cancer	0.000175	0.000433	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—SRC—urinary bladder cancer	0.000175	0.000433	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—EGFR—urinary bladder cancer	0.000173	0.00043	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EP300—urinary bladder cancer	0.000173	0.00043	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—NCOR1—urinary bladder cancer	0.000173	0.000428	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GSTM1—urinary bladder cancer	0.000173	0.000428	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—SRC—urinary bladder cancer	0.000169	0.000418	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—ERBB2—urinary bladder cancer	0.000167	0.000414	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—FGFR3—urinary bladder cancer	0.000167	0.000413	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GPX1—urinary bladder cancer	0.000165	0.00041	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—TNF—urinary bladder cancer	0.000165	0.000409	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MYC—urinary bladder cancer	0.000164	0.000407	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—KRAS—urinary bladder cancer	0.000164	0.000406	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—FGFR3—urinary bladder cancer	0.000163	0.000403	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ERCC2—urinary bladder cancer	0.000162	0.000402	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—S100B—urinary bladder cancer	0.000161	0.000398	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CXCL8—urinary bladder cancer	0.000159	0.000393	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ESR1—urinary bladder cancer	0.000158	0.000391	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—HRAS—urinary bladder cancer	0.000158	0.000391	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MYC—urinary bladder cancer	0.000156	0.000388	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CREBBP—urinary bladder cancer	0.000154	0.000381	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—EGFR—urinary bladder cancer	0.000153	0.00038	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—EGFR—urinary bladder cancer	0.000153	0.000379	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDH1—urinary bladder cancer	0.000153	0.000378	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—MTHFR—urinary bladder cancer	0.000153	0.000378	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL2—urinary bladder cancer	0.000152	0.000376	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MYC—urinary bladder cancer	0.000151	0.000374	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CCND1—urinary bladder cancer	0.000148	0.000366	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EGFR—urinary bladder cancer	0.000148	0.000366	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—KRAS—urinary bladder cancer	0.000145	0.000359	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—KRAS—urinary bladder cancer	0.000145	0.000358	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NCOR1—urinary bladder cancer	0.000144	0.000358	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MMP9—urinary bladder cancer	0.000144	0.000356	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000143	0.000354	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTEN—urinary bladder cancer	0.000143	0.000353	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CREBBP—urinary bladder cancer	0.000142	0.000352	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—KRAS—urinary bladder cancer	0.00014	0.000346	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—HRAS—urinary bladder cancer	0.000139	0.000345	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CREBBP—urinary bladder cancer	0.000138	0.000343	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IGF1—urinary bladder cancer	0.000137	0.000339	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—EGFR—urinary bladder cancer	0.000136	0.000337	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EP300—urinary bladder cancer	0.000136	0.000337	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—urinary bladder cancer	0.000135	0.000334	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SRC—urinary bladder cancer	0.000132	0.000328	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ERBB2—urinary bladder cancer	0.000129	0.000319	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—KRAS—urinary bladder cancer	0.000129	0.000318	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TP53—urinary bladder cancer	0.000128	0.000318	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—RHOA—urinary bladder cancer	0.000128	0.000318	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TERT—urinary bladder cancer	0.000127	0.000315	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—RHOA—urinary bladder cancer	0.000125	0.00031	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TP53—urinary bladder cancer	0.000124	0.000307	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PPARG—urinary bladder cancer	0.000124	0.000307	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—HRAS—urinary bladder cancer	0.000123	0.000305	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—HRAS—urinary bladder cancer	0.000123	0.000304	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CREBBP—urinary bladder cancer	0.000119	0.000294	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—ERBB2—urinary bladder cancer	0.000119	0.000294	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—HRAS—urinary bladder cancer	0.000119	0.000294	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MYC—urinary bladder cancer	0.000119	0.000294	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGFR3—urinary bladder cancer	0.000117	0.000289	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL2—urinary bladder cancer	0.000117	0.000289	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTGS2—urinary bladder cancer	0.000116	0.000288	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ERBB2—urinary bladder cancer	0.000116	0.000287	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EGFR—urinary bladder cancer	0.000116	0.000287	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ESR1—urinary bladder cancer	0.000113	0.000281	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1A—urinary bladder cancer	0.00011	0.000273	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CXCL8—urinary bladder cancer	0.00011	0.000272	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PTEN—urinary bladder cancer	0.00011	0.000272	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—KRAS—urinary bladder cancer	0.00011	0.000271	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—HRAS—urinary bladder cancer	0.000109	0.000271	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL2—urinary bladder cancer	0.000105	0.00026	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EP300—urinary bladder cancer	0.000105	0.000259	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCND1—urinary bladder cancer	0.000102	0.000254	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—SRC—urinary bladder cancer	0.000102	0.000252	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1A—urinary bladder cancer	0.000102	0.000252	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTEN—urinary bladder cancer	0.000101	0.000251	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MMP9—urinary bladder cancer	9.95e-05	0.000246	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CREBBP—urinary bladder cancer	9.94e-05	0.000246	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1A—urinary bladder cancer	9.91e-05	0.000246	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTEN—urinary bladder cancer	9.89e-05	0.000245	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IGF1—urinary bladder cancer	9.82e-05	0.000243	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—urinary bladder cancer	9.74e-05	0.000241	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTGS2—urinary bladder cancer	9.73e-05	0.000241	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EP300—urinary bladder cancer	9.67e-05	0.000239	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EP300—urinary bladder cancer	9.43e-05	0.000234	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SRC—urinary bladder cancer	9.4e-05	0.000233	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—HRAS—urinary bladder cancer	9.31e-05	0.000231	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SRC—urinary bladder cancer	9.17e-05	0.000227	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RHOA—urinary bladder cancer	8.99e-05	0.000223	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGFR—urinary bladder cancer	8.92e-05	0.000221	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTEN—urinary bladder cancer	8.49e-05	0.00021	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KRAS—urinary bladder cancer	8.43e-05	0.000209	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MYC—urinary bladder cancer	8.42e-05	0.000209	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB2—urinary bladder cancer	8.32e-05	0.000206	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGFR—urinary bladder cancer	8.24e-05	0.000204	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MYC—urinary bladder cancer	8.22e-05	0.000204	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—EP300—urinary bladder cancer	8.1e-05	0.000201	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGFR—urinary bladder cancer	8.04e-05	0.000199	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CXCL8—urinary bladder cancer	7.89e-05	0.000196	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KRAS—urinary bladder cancer	7.78e-05	0.000193	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KRAS—urinary bladder cancer	7.59e-05	0.000188	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL2—urinary bladder cancer	7.54e-05	0.000187	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCND1—urinary bladder cancer	7.35e-05	0.000182	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HRAS—urinary bladder cancer	7.17e-05	0.000178	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP9—urinary bladder cancer	7.14e-05	0.000177	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.11e-05	0.000176	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTEN—urinary bladder cancer	7.1e-05	0.000176	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EP300—urinary bladder cancer	6.77e-05	0.000168	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—urinary bladder cancer	6.75e-05	0.000167	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HRAS—urinary bladder cancer	6.62e-05	0.000164	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SRC—urinary bladder cancer	6.58e-05	0.000163	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HRAS—urinary bladder cancer	6.45e-05	0.00016	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MYC—urinary bladder cancer	5.9e-05	0.000146	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGFR—urinary bladder cancer	5.77e-05	0.000143	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KRAS—urinary bladder cancer	5.45e-05	0.000135	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—urinary bladder cancer	4.84e-05	0.00012	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HRAS—urinary bladder cancer	4.63e-05	0.000115	CbGpPWpGaD
